Dana-Farber Cancer Institute (DFCI) conducted a retrospective analysis of 41 patients with metastatic breast cancer (25 HER2-positive, 16 HER2-negative) treated with trastuzumab deruxtecan (T-DXd ...

In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...

and trastuzumab deruxtecan as a monotherapy. This review examines the role of HER2 as a biomarker in colorectal cancer, focusing on its molecular characteristics, the clinical profiles of patients ...

Exclusive tours of Boston architecture & firms Unparalleled networking with peers & experts Largest expo in our industry featuring 600 brands Whether you’re an architect, design professional, engineer ...

BLA accepted for Priority Review Fam-trastuzumab deruxtecan-nxki (AstraZeneca and Daiichi Sankyo) Human epidermal growth factor receptor 2 (HER2)-directed antibody + topoisomerase inhibitor conjugate ...

Nothing Phone 3 could cost Rs 60,000 in India, set to launch on July 1: Check design, camera and more Smartphone maker Nothing has confirmed that its most expected Nothing Phone 3 is all set to ...

BLA accepted for Priority Review Fam-trastuzumab deruxtecan-nxki (AstraZeneca and Daiichi Sankyo) Human epidermal growth factor receptor 2 (HER2)-directed antibody + topoisomerase inhibitor ...

Conversely, higher TOPO1 protein correlated with worse outcomes. In patients with metastatic breast cancer receiving fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu), better outcomes were linked with ...

One of the trials that presented results of this type of drug was Destiny-Breast09. The study evaluated the combination of the Trojan horse trastuzumab-deruxtecan with pertuzmab, a Her2 protein ...

With a median progression-free survival of more than three years, the DESTINY-Breast09 results show trastuzumab deruxtecan combined with pertuzumab has the potential to become a new first-line ...